Form 4: Xeris Biopharma Director Sells Shares Under 10b5-1 Plan

Xeris Biopharma Holdings, Inc. Director James Aloysius Brady sold 10,834 shares of common stock at a weighted average price of $5.5414 per share under a pre-arranged trading plan.

Summary

• Director James Aloysius Brady of Xeris Biopharma Holdings, Inc. reported a sale of common stock.
• The transaction involved the disposition of 10,834 shares.
• The shares were sold on March 30, 2026, at a weighted average price of $5.5414 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan.
• Following this transaction, Mr. Brady directly owns 89,166 shares of Xeris Biopharma Holdings, Inc. common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While the sale was pre-planned under a Rule 10b5-1 plan, reducing the implication of immediate market timing, any insider selling can be interpreted as a lack of increasing confidence.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, as it might suggest a lack of confidence, although such sales are often for personal financial planning or diversification.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which is solely a report of an insider transaction.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's perception of future company performance. In the biopharma sector, such sales are often viewed in conjunction with clinical trial progress, regulatory milestones, and commercialization efforts.

Comparison to Industry Standards

• This filing is a standard insider transaction report, common across all industries. Insider selling, particularly under a pre-arranged 10b5-1 plan, is a routine occurrence for personal financial planning and diversification, and is not inherently indicative of company-specific issues when compared to similar transactions by executives at companies like Pfizer or Johnson & Johnson.

Stakeholder Impact

• Shareholders: May interpret the sale as a slight negative signal, though the 10b5-1 plan suggests personal financial planning rather than a direct market timing decision.

Key Dates

Recommendation

This Form 4 reports a routine insider sale under a 10b5-1 plan, which is typically for personal financial management and diversification rather than a direct signal about the company's immediate prospects. While insider selling can sometimes be a yellow flag, the pre-scheduled nature and the amount relative to the director's remaining holdings do not warrant a change from a 'hold' position based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

Xeris Biopharma Holdings, XERS, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Beneficial Ownership